FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
February 13th 2020The FDA approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy.
Synchronous Bilateral Lung Cancer With Discordant Histology
Medical oncologsts discuss the case of a 70-year old woman with synchronous multiple primary lung cancer.